Use the hyperlinks, where available to access additional clinical trial information.
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects With Extensive Stage Small Cell Lung Cancer
This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy. In the experimental arm, patients will receive Rovalpituzumab tesirine (0.3mg/kg) / dexamethasone (8mg) every 6 weeks; omitting every third cycle. In the second arm, patients will receive placebo every 6 weeks; omitting every third cycle.